CoChat

Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011

Open access
Woods, Scott W., Addington, Jean, Bearden, Carrie E., Cadenhead, Kristin S., Cannon, Tyrone D., Cornblatt, Barbara A., Mathalon, Daniel H., Perkins, Diana O., Seidman, Larry J., Tsuang, Ming T., Walker, Elaine F., McGlashan, Thomas H. · 2013 · Schizophrenia Research
Cited by 40

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background Antipsychotic medication use rates have generally been rising among youth with psychiatric disorders, but little is known about use rates of antipsychotics or other psychotropic medications in patients at high risk for psychosis. Method Baseline psychotropic medication use rates were compared in two research cohorts of patients at high risk for psychosis that enrolled between 1998-2005 (n=391) and 2008-2011 (n=346). Treatment durations and antipsychotic doses were described for cohort 2. Results Median age was 17 years in cohort 1 and 18 years in cohort 2. The rate of prescription of any psychotropic at baseline was roughly 40% for each cohort. Antipsychotic prescription rates were 24% among sites that permitted baseline antipsychotic use in cohort 1 and 18% in the cohort 2; the decline did not quite reach statistical significance (p=0.064). In cohort 2 the mean±sd baseline chlorpromazine-equivalent dose was 121±108 mg/d, and lifetime duration of antipsychotic treatment was 3.8±5.9 months. Discussion Although the rate of antipsychotic prescription among high-risk youth may have fallen slightly, the nearly one-in-five rate in the second cohort still constitutes a significant exposure. Mitigating factors were that doses and durations of treatment were low. As for other nonpsychotic conditions, it is incumbent on our field to develop alternative treatments for high-risk patients and to generate additional evidence for or against the efficacy of antipsychotics to help define their appropriate role if alternative treatments fail.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.schres.2013.05.019

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 40

Metadata

Authors
Woods, S. W., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., & McGlashan, T. H.
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2013-08
Volume
148
Issue
1-3
Pages
99-104
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2084802730
Cited by
40
References
11
FWCI
3.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. https://app.cochat.ai/papers/10.1016/j.schres.2013.05.019
The paper
Woods, S. W., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., & McGlashan, T. H. (2013). Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. Schizophrenia Research. https://doi.org/10.1016/j.schres.2013.05.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.